STOCKWATCH
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultMay 13, 2026, 06:09 AM

Dominari Holdings Q1 Net Loss Widens to $57.36M; Revenue Jumps to $35.81M

AI Summary

Dominari Holdings Inc. reported a net loss attributable to common stockholders of $57.36 million for the first quarter of 2026, a significant increase from $32.49 million in the prior year period. Despite this, total revenue saw a substantial jump to $35.81 million, primarily driven by underwriting services. The company's operating expenses, particularly compensation and benefits, also increased significantly. As of March 31, 2026, cash and cash equivalents decreased to $27.48 million, and the company experienced a net cash outflow from operating activities.

Key Highlights

  • Net loss attributable to common stockholders was $(57.36) million in Q1 2026, up from $(32.49) million in Q1 2025.
  • Total revenue increased to $35.81 million in Q1 2026, from $7.24 million in Q1 2025.
  • Underwriting services revenue surged to $32.95 million in Q1 2026, from $5.61 million in Q1 2025.
  • Compensation and benefits expense rose to $68.16 million in Q1 2026, from $15.46 million in Q1 2025.
  • Cash and cash equivalents stood at $27.48 million as of March 31, 2026, down from $34.01 million.
  • Total assets decreased to $85.32 million as of March 31, 2026, from $112.91 million at Dec 31, 2025.
  • Net cash used in operating activities was $(28.94) million in Q1 2026, compared to $1.24 million provided in Q1 2025.
  • Total stockholders' equity decreased to $31.58 million as of March 31, 2026, from $69.37 million.
DOMH
Biotechnology: Pharmaceutical Preparations
Dominari Holdings Inc.

Price Impact